Bioventix Share Discussion Threads

[nfs] 03/6/2016 14:04

Thanks so muchI am booking now,and joining sharesoc,about time I did

[davidosh] 03/6/2016 12:13

The next Richmond supper will be on Monday 6th June with Bioventix & their CEO Peter Harrison presenting. Register

I think there are only five places left.

[ragehammer] 03/6/2016 10:34

Details here: hxxp://www.sharesoc.org/richmondjune.html

[nfs] 03/6/2016 10:14

When is the presentation and how can I go?I have been away for some time without access so I apologise for asking thisThanks

[tadders2] 01/6/2016 18:36

Thanks for that. I spoke to Mr Harrison a few weeks ago and would very much like to see the presentation . Have been a shareholder for several years and have a very positive view of the company.

[davidosh] 01/6/2016 18:13

You may be very lucky as a few of these have been filmed recently but not sure if it has been planned for this one. They are usually on the PI World website after the event.

[tadders2] 01/6/2016 18:08

Would love to go to the presentation in Richmond but it's a long journey from Northumberland. Will the presentation be taped?

[davidosh] 01/6/2016 17:51

Bioventix mentioned on the radio

[tadders2] 31/5/2016 12:47

Totally agree.

[a1samu] 31/5/2016 12:30

Quietly building a portfolio of products.

Wonderfully positive approach to investing!

[stepone68] 31/5/2016 12:11

Probably because any potential is years away. This is only at the research stage, and could quite easily come to nothing.

[tadders2] 31/5/2016 10:46

This new pre-diagnostic test for Alzheimer's could become a standard test included in an annual health for over 50s. That being the case this has enormous potential . Surprised there ha seen no real move in the share price

[impvesta] 31/5/2016 07:45

Collaboration with a Norwegian company to develop and provide antibodies for a dementia test:

[a1samu] 15/5/2016 09:40

and the dividend will be nearer 50p if all previous increases are considered?!

[nfs] 14/5/2016 13:44

Bioventix management like to have cautious forecasts in the marketI think most people here think eps will be 60-65p rather then 54p for this financial yearAlso we know that some vitamin d revenues will drop off but the troponin incoming earnings are not yet fixed as to timing And abcam is a lot bigger

[johnsmith321] 14/5/2016 09:25

Also Abcam sell alot more different products giving a more diversified revenue stream. Giving more stability.

[johnsmith321] 14/5/2016 09:23

I was also wondering this. Abcam have a longer established history of continuous,improving profitability. PE was to high for me though when I was considering Abcam. Bioventix is a bargain by comparison. It is also a defensive stock.

[a1samu] 14/5/2016 08:34

why is Abcam on 32 p/e and Bioventix on 20 only?

[apad] 09/4/2016 11:25

Thanks,j. I shall take some time to try and understand your response.
I'd hoped there might be somebody with specialist knowledge here.
apad

[johnsmith321] 09/4/2016 10:08

You can make antibodies to most proteins in rabbits. No real market for ricin antibodies. Most of the commercially interesting antigens are not toxic.

I think Abcam could still buy Bioventix in the future. They each target different markets so they do not overlap.

[apad] 09/4/2016 08:17

"in vivo systems are limited when it comes to generating antibodies to highly toxic antigens, he said, citing ricin as one target they have taken on. Likewise, if a human protein target is too similar to the rabbit version, the rabbit will not generate antibodies to it, making it difficult to produce reagents in this way.

"I think what [Abcam] is trying to do is have the ability to get at affinity reagents no matter what the immunogen is," Weiner said. "And so there are limitations in phage display, and there are limitations to rabbit, but [combining the two] allows you to go after a larger immunogen space."

Does this mean that rabbit will compete more directly with sheep?
Does this explain why ABCAM will not buy BVXP?

apad

[apad] 09/4/2016 08:17

"in vivo systems are limited when it comes to generating antibodies to highly toxic antigens, he said, citing ricin as one target they have taken on. Likewise, if a human protein target is too similar to the rabbit version, the rabbit will not generate antibodies to it, making it difficult to produce reagents in this way.

"I think what [Abcam] is trying to do is have the ability to get at affinity reagents no matter what the immunogen is," Weiner said. "And so there are limitations in phage display, and there are limitations to rabbit, but [combining the two] allows you to go after a larger immunogen space."

Does this mean that rabbit will compete more directly with sheep?
Does this explain why ABCAM will not buy BVXP?

apad

[apad] 09/4/2016 08:17

"in vivo systems are limited when it comes to generating antibodies to highly toxic antigens, he said, citing ricin as one target they have taken on. Likewise, if a human protein target is too similar to the rabbit version, the rabbit will not generate antibodies to it, making it difficult to produce reagents in this way.

"I think what [Abcam] is trying to do is have the ability to get at affinity reagents no matter what the immunogen is," Weiner said. "And so there are limitations in phage display, and there are limitations to rabbit, but [combining the two] allows you to go after a larger immunogen space."

Does this mean that rabbit will compete more directly with sheep?
Does this explain why ABCAM will not buy BVXP?

apad

[johnsmith321] 23/3/2016 21:58

Hi Bamboo interesting observation. Alot of shares were sold today (£950,000). The share price decline is probably only short term. As the interim and outlook were very positive and stock is not over valued on P/E or div yield.